Shares of BioCryst Pharmaceuticals (BCRX) soared 5.33% in pre-market trading on Monday, as investors eagerly anticipate the company's third-quarter earnings report scheduled for release at 7:00 AM. This significant uptick comes after a period of modest gains, with the stock climbing about 2% over the past month.

The pharmaceutical company, known for its focus on rare diseases, is expected to report earnings of $0.04 per share for the quarter. Analysts have set price targets far above current levels, reflecting optimism about BioCryst's future prospects. This positive sentiment is supported by the company's recent financial performance, which has shown double-digit annual growth in both revenue and net income.

While BioCryst's share price has experienced some volatility over the past year, with a 13% decline in total shareholder return over the last 12 months, investors appear to be focusing on the company's improving fundamentals and growth potential. The pre-market surge suggests that market participants are positioning themselves ahead of what could be a strong earnings report, potentially marking a turning point for the stock's recent performance.